If you have been reading about lactam bridge and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-11-06. Numbers and descriptions here follow the published literature rather than marketing material.
Melanotan-2 is handled in the laboratory as a lyophilised powder that dissolves readily in water, dimethyl sulfoxide and dimethylformamide, with limited solubility in ethanol. Stock solutions prepared in an organic solvent often precipitate when diluted into aqueous buffer, so gradual dilution with mixing is standard practice. The peptide carries a tryptophan residue and a histidine residue, both sensitive to oxidation and to alkaline conditions. Working solutions are therefore kept near neutral to slightly acidic pH, protected from light, and consumed within the same working session whenever that is practical.
Solid peptide kept dry at minus twenty degrees Celsius, shielded from light and moisture, is generally considered stable for extended periods. Solutions are divided into single-use aliquots and held at minus twenty or minus eighty degrees Celsius, because repeated freeze-thaw cycles promote aggregation and loss of material to container surfaces. Hydrolysis of the backbone and oxidation of tryptophan are the principal degradation routes in aqueous solution, and both accelerate at ambient temperature. Hygroscopic uptake after a vial is opened can also shift the actual mass weighed, which affects any concentration calculated from it.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilised material may be hygroscopic |
| Solubility class | Soluble in water, DMSO and DMF | Dilution into aqueous buffer can cause precipitation |
| Storage of solid | Minus 20 degrees C, desiccated, dark | Aliquot to limit repeated opening of the vial |
| Storage of solution | Minus 20 to minus 80 degrees C, aliquoted | Avoid repeated freeze-thaw cycles |
| Identity method | Reversed-phase HPLC with mass spectrometry | Retention time and mass are checked together |
Regulatory treatment of this peptide varies by country. It holds no marketing authorization as a medicine in the United States, the European Union, or most other jurisdictions. Some countries classify products containing it as prescription-only or unlicensed medicines, which restricts lawful supply. Authorities have issued public notices warning that unregulated products may contain undeclared or incorrect ingredients. The molecule also appears on prohibited lists for competitive sport. These measures address supply oversight rather than any approved therapeutic role.
Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.
Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Magnesium is a chemical element; it has symbol Mg and atomic number 12. It is a shiny gray metal having a low density, low melting point, and high chemical reactivity. Like the other alkaline earth metals (group 2 of the periodic table), it occurs naturally only in combination with other elements and almost always has an oxidation state of +2. It reacts readily with air to form a thin passivation coating of magnesium oxide that inhibits further corrosion of the metal. The free metal burns with a brilliant-white light. The metal is obtained mainly by electrolysis of magnesium salts obtained from brine. It is less dense than aluminium and is used primarily as a component in strong and lightweight alloys that contain aluminium. In the cosmos, magnesium is produced in large, aging stars by the sequential addition of three helium nuclei to a carbon nucleus. When such stars explode as supernovas, much of the magnesium is expelled into the interstellar medium, where it may recycle into new star systems. Magnesium is the eighth most abundant element in Earth's crust and the fourth most common element in the Earth (after iron, oxygen and silicon), making up 13% of the planet's mass and a large fraction of the planet's mantle. It is the third most abundant element dissolved in seawater, after sodium and chlorine. This element is the eleventh most abundant element by mass in the human body and is essential to all cells and some 300 enzymes. Magnesium ions interact with polyphosphate compounds such as ATP, DNA, and RNA. Hundreds of enzymes require magnesium ions to function.
First, 2-chloro-6-methoxy-3-nitropyridine and 2-aminopropane-1,3-diol undergo nucleophilic aromatic substitution (SNAr) to form a diol, which is then protected by 2,2-dimethoxypropane to form a ketal intermediate. The intermediate is reduced with hydrogen catalyzed by Pd/C to afford an amine, which then immediately goes through substitution with ethyl bromoacetate. The resulting compound is treated with NaH, and is then oxidized with MnO2 to form the pyrazinone ring. The ketal is deprotected with aqueous HCl to regenerate the diol, and is then treated with methanesulfonic anhydride and triethylamine to form the final ring of the tricyclic core. The resulting compound goes through substitution with tert-butyl piperidin-4-ylcarbamate, acidic deprotection of the amino group, and chiral preparative HPLC to give the enantio-pure penultimate amine intermediate. Finally, a reductive amination is performed, and the product is treated with HCl in diethyl ether to form gepotidacin as a hydrochloride. This route consists of 11 steps, with 8 steps aimed at the formation of the tricyclic core.
Committee on Armed Services Subcommittee on Cybersecurity Subcommittee on Emerging Threats and Capabilities Subcommittee on Seapower Committee on Commerce, Science, and Transportation Subcommittee on Space and Science (Ranking Member) Subcommittee on Communications, Media, and Broadband Subcommittee on Surface Transportation, Maritime, Freight, and Ports
== Testing for HHV-6 == The table below presents a comprehensive overview of various diagnostic tests used to detect human herpesvirus 6 (HHV-6), detailing their ability to distinguish between active and latent infections. It also includes insights on the interpretation of test results, identifies providers that offer these tests, and indicates which methods are suitable for detecting HHV-6A in the endometrial lining—an important consideration for evaluating potential causes of infertility in women. The table serves as a guide for healthcare professionals to select appropriate diagnostic tests for HHV-6.
Sources: en.wikipedia.org
== Impact == According to the United Nations Office for the Coordination of Humanitarian Affairs (OCHA), the civilian infrastructure in Eastern Afghanistan suffered as a result of hostilities. As of late April 2026, about 19 health facilities were closed, suspended or operating at reduced capacity. About 78,000 people suffered from limited access to healthcare as a consequence. Education services also faced disruptions with more than 13,000 students affected in Kunar and Nangarhar provinces. Water systems were damaged in at least six villages. Between late February and late April, approximately 100,900 people were displaced across Khost, Kunar, Nangarhar, Nuristan, Paktia, and Paktika provinces. Continuous shelling and unexploded ordnances constrained access for humanitarian operations in some of these provinces. Death counts, especially the toll on civilians, remained disputed during the course of the conflict. While the Taliban claimed 800 Afghan civilians were killed by April, Pakistan claimed that its forces killed over 640 militants and 850 'facilitators.' According to Azizullah Aziz, a journalist and eastern zone coordinator of the Afghan Journalists Safety Committee, most of the attacks were carried out "at night, during Ramadan." Amid the conflict, the deportation of Afghans from Pakistan continued. According to the International Organization for Migration (IOM) in Kandahar, while the deportations through the Torkham crossing paused in March, repatriations continued through the Spin Boldak crossing.
== Function == This gene encodes a transmembrane transporter that likely plays a role in monocarboxylic acid transport. A mutation in this gene has been associated with juvenile cataracts with microcornea and renal glucosuria. [provided by RefSeq, Mar 2010].
He is dressed in a bordered and turned-up, collarless tunic with close-fitting sleeves. The tunic, which reaches slightly above the knee, is belted. The pants are of the same color and have the same border. He wears gray calf boots with cruciate ligaments that run under the sole. The figure behind holds a wreath and a kind of censer, is dressed in a black belted lap jacket with tight-fitting sleeves, which is provided with a red border all around, and an ample green dress. Their hair is cut straight to the nuque, a hair style also referenced for the people of Kucha in the contemporary Chinese chronicles Jin Shu. A kneeling monk appeared next to the top left corner of the main mural, in a red robe and with ocher shorn hair, engaged in shaping a ceremonial jar with a hammer, while behind him appeared a painter wearing a tunic similar to those of the donors on the other side, but whose head only remained.
Sources: en.wikipedia.org
Purity is normally stated as an area percentage from high-performance liquid chromatography, for example ninety-five or ninety-eight percent. That figure describes the proportion of ultraviolet-absorbing material eluting as the main peak. It says nothing about water content, counterions, residual solvents or mass fraction of the peptide itself.
Peptides are commonly isolated as acetate or trifluoroacetate salts, and the counterion contributes to total mass. Two vials with identical peptide content can therefore differ in weight and in measured response. Residual trifluoroacetate is also relevant in cell-based work because it can influence membrane behaviour.
Degradation products are often closely related to the parent molecule, making them hard to resolve with a single method. Counterion variability adds a further source of scatter between laboratories. Because no pharmacopoeial monograph exists for melanotan-2, groups rely on method-specific validation rather than a shared reference standard.
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.